Flora Lands ¥230 Million in Funding
Flora, a Kyoto, Japan-based femtech startup that provides an AI-powered healthcare platform for women, has raised approximately ¥230 million, bringing its total funding to about ¥500 million.
The round includes investments from Ritsumeikan Social Impact Fund, Nagase & Co., Ltd. (via its CVC fund), and PE&HR Co., Ltd., along with loans from financial institutions.
Flora Use of Funds
The company will use the funds to enhance its Wellflow platform, expand its AI-powered data services, grow its consumer healthcare app, scale internationally across Asia, and strengthen hiring in engineering and data roles.
Founded by Anna Creschenko, Flora is a femtech company focused on addressing the global gender data gap in healthcare through AI- and data-driven solutions. The company leverages a dataset of approximately 200,000 users and proprietary AI algorithms to build products that support women’s health across all life stages, including menstruation, fertility, pregnancy, postpartum, and menopause. Flora generates insights for healthcare, workplace productivity, and product development. Its core offerings include Wellflow, a corporate femtech platform that supports employee well-being and workplace productivity; Flora Expert, a data-driven business development solution enabling gender-informed innovation; and Moonly, a consumer healthcare app.
Funding Details
Company: Flora Co., Ltd.
Raised: ¥230.0M
Round: Undisclosed
Funding Date: April 2026
Lead Investor: Ritsumeikan Social Impact Fund
Additional Investors: Nagase & Co., Ltd. (Nagase Future Fund), PE&HR Co., Ltd., financial institutions
Company Website: https://biz.flora-tech.jp/
Software Category: Femtech / AI Healthcare